Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Embrace TDD: Prospective, Multi-Center, Post Market Study to Evaluate Intrathecal (IT) Morphine as an Alternative to Systemic Opioids for the Treatment of Chronic, Intractable, Non-Malignant Primary Back Pain With or Without Leg Pain

NCT03761277 is registered in ClinicalTrials.gov with MedtronicNeuro as lead sponsor.

NCT NCT03761277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03761277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Embrace TDD: Prospective, Multi-Center, Post Market Study to Evaluate Intrathecal (IT) Morphine as an Alternative to Systemic Opioids for the Treatment of Chronic, Intractable, Non-Malignant Primary Back Pain With or Without Leg Pain
Lead sponsor
MedtronicNeuro
Phase
Phase 4
Overall status
Completed
Start date
January 16, 2019
Completion date
December 6, 2021
Enrollment
93 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic non-malignant pain, chronic pain, pain, back, pain, leg